

## NCCN Small Cell Lung Cancer V.1.2012 – Follow-up – 05/23/11

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
LNT-1 Internal request: Add temozolomide, sunitinib, and everolimus as treatment options for lung neuroendocrine carcinoma.	Based upon data noted in the references, the panel consensus was to add temozolomide, sunitinib, and everolimus as treatment options for stage IIIb, IV or unresectable low- or intermediate-grade lung neuroendocrine carcinoma.	Ekebald S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991; Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410; Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318.	24	0	0